Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 21 articles: HTML format

Single Articles

September 2025
1. MAMIDI N, Das SK, Fisher PB
   NR2F1 and mTORC1 provide the bridge between melanoma dormancy and therapeutic resistance.
   J Clin Invest. 2025;135:e197764.
   PubMed     Abstract available
   
   
   
2. TIAGO M, Purwin TJ, Stefanski CD, da Silva RO, et al
   Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma.
   J Clin Invest. 2025;135:e178446.
   PubMed     Abstract available
   
   
   
3. XIAO L, Ai YL, Mi XY, Liang H, et al
   cGAS activation converges with intracellular acidification to promote STING aggregation and pyroptosis in tumor models.
   J Clin Invest. 2025;135:e188872.
   PubMed     Abstract available
   
   
   July 2025
4. KHAN I, Rodriguez-Brotons A, Bhattacharjee A, Bezrookove V, et al
   Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade.
   J Clin Invest. 2025 Jul 10:e185220. doi: 10.1172/JCI185220.
   PubMed     Abstract available
   
   
   May 2025
5. WANG Y, Ohnuki H, Tran AD, Wang D, et al
   Induced clustering of SHP2-depleted tumor cells in vascular islands restores sensitivity to MEK/ERK inhibition.
   J Clin Invest. 2025;135:e181609.
   PubMed     Abstract available
   
   
   
6. TORRES ACOSTA MA, Gurkan JK, Liu Q, Mambetsariev N, et al
   AMPK is necessary for Treg functional adaptation to microenvironmental stress during malignancy and viral pneumonia.
   J Clin Invest. 2025;135:e179572.
   PubMed     Abstract available
   
   
   
7. HYUN H, Sun B, Yazdimamaghani M, Wielgus A, et al
   Tumor-specific surface marker-independent targeting of tumors through nanotechnology and bioorthogonal glycochemistry.
   J Clin Invest. 2025;135:e184964.
   PubMed     Abstract available
   
   
   April 2025
8. STAEGER R, Tastanova A, Ghosh A, Winkelbeiner N, et al
   Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T-cells in uveal melanoma patients.
   J Clin Invest. 2025 Apr 29:e181464. doi: 10.1172/JCI181464.
   PubMed     Abstract available
   
   
   January 2025
9. ZHANG H, Wang Z, Wu J, Zheng YQ, et al
   Endothelial STING-JAK1 interaction promotes tumor vasculature normalization and antitumor immunity.
   J Clin Invest. 2025;135:e180622.
   PubMed     Abstract available
   
   
   December 2024
10. WEN C, Wang L, Piffko A, Chen D, et al
    YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production.
    J Clin Invest. 2024;134:e181612.
    PubMed     Abstract available
    
    
    October 2024
11. NIELSEN AJ, Albert GK, Sanchez A, Chen J, et al
    DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors.
    J Clin Invest. 2024;134:e180278.
    PubMed     Abstract available
    
    
    September 2024
12. LI ZJ, He B, Domenichini A, Satiaputra J, et al
    Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models.
    J Clin Invest. 2024;134:e179860.
    PubMed     Abstract available
    
    
    
13. VERMA S, Budhu S, Serganova I, Dong L, et al
    Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models.
    J Clin Invest. 2024;134:e177606.
    PubMed     Abstract available
    
    
    May 2024
14. CONWAY JR, Gillani R, Crowdis J, Reardon B, et al
    Somatic structural variants drive distinct modes of oncogenesis in melanoma.
    J Clin Invest. 2024 May 14:e177270. doi: 10.1172/JCI177270.
    PubMed     Abstract available
    
    
    
15. HUANG F, Goncalves C, Bartish M, Remy-Sarrazin J, et al
    Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
    J Clin Invest. 2024;134:e181575.
    PubMed    
    
    
    April 2024
16. ZHAN Y, Guo J, Yang W, Goncalves C, et al
    MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
    J Clin Invest. 2024;134:e181338.
    PubMed    
    
    
    February 2024
17. WU M, Hanly A, Gibson F, Fisher R, et al
    The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.
    J Clin Invest. 2024 Feb 1:e171063. doi: 10.1172/JCI171063.
    PubMed     Abstract available
    
    
    December 2023
18. KNIGHT DA, Ngiow SF, Li M, Parmenter T, et al
    Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
    J Clin Invest. 2023;133:e177489.
    PubMed    
    
    
    November 2023
19. AJITH A, Mamouni K, Horuzsko DD, Musa A, et al
    Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance.
    J Clin Invest. 2023;133:e167951.
    PubMed     Abstract available
    
    
    August 2023
20. HUANG F, Cai F, Dahabieh MS, Gunawardena K, et al
    Peroxisome disruption alters lipid metabolism and potentiates anti-tumor response with MAPK-targeted therapy in melanoma.
    J Clin Invest. 2023 Aug 24:e166644. doi: 10.1172/JCI166644.
    PubMed     Abstract available
    
    
    July 2023
21. OZBAY KURT FG, Lasser S, Arkhypov I, Utikal J, et al
    Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target.
    J Clin Invest. 2023;133:e170762.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.